Considerations for powering a clinical proteomics study: Normal variability in the human plasma proteome.

The plasma proteome is a key target for identifying disease biomarkers. However, variability in plasma protein levels remains poorly characterized in large populations. Prior research has shown that 2-D DIGE can quantify thousands of protein spots while preserving isoform information. Yet, few studies have examined normal variability in healthy individuals using this method. This gap motivated the current work to assess sample size requirements for clinical proteomics. No prior work had resolved how many samples are needed to detect meaningful proteomic changes. Establishing these parameters is essential for designing adequately powered studies. Variability estimates are crucial for determining statistical power. This study addresses these knowledge gaps by analyzing plasma from 60 healthy volunteers.

The aim was to estimate sample size requirements for clinical proteomics using 2-D DIGE. Researchers focused on normal variability in plasma proteins from healthy individuals. They sought to determine how many samples are needed to detect proteomic changes. The study compared paired versus non-paired designs to assess sensitivity. A two-fold change in protein spot volume was used as the detection threshold. The goal was to provide guidance for future biomarker studies. This work fills a critical gap in understanding power requirements. The findings will help design more efficient clinical proteomics experiments.

Plasma samples from 60 healthy volunteers were analyzed using 2-D DIGE. Two samples per individual were collected seven days apart. This allowed comparison of paired versus non-paired designs. Protein spot intensities were quantified across thousands of spots. Statistical parameters included a two-fold change, α of 0.05, and power of 0.8. Sample groups of 20 were used to estimate detection sensitivity. Interbatch variability was measured to assess reproducibility. The study focused on normal variability rather than disease-specific changes.

Using 20 samples, 1742 spots showed detectable changes with longitudinal sampling. Non-paired groups detected 1206 spots under the same parameters. Longitudinal sampling improved sensitivity by 43%. Interbatch variability was low compared to detection thresholds. This suggests 2-D DIGE is robust for large-scale studies. The two-fold change threshold was consistent across batches. Sample size requirements were estimated for future studies. These results provide concrete guidance for proteomics study design.

The study found that 20 samples can detect many proteomic changes using 2-D DIGE. Longitudinal sampling significantly improved sensitivity. The detection threshold of two-fold was achievable with this sample size. Interbatch variability was low, confirming method robustness. These findings help guide future clinical proteomics studies. The results apply specifically to plasma from healthy individuals. They do not suggest that smaller sample sizes are sufficient. The study supports using paired designs to maximize detection power.